Stage III NSCLC RWE in Chinese Patients
Study identifier:D4194R00009
ClinicalTrials.gov identifier:NCT04023812
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Real-World Molecular Testing, Treatment Patterns and Clinical Outcomes in Chinese Patients with Stage III NSCLC- A Prospective, Non-Interventional Study(MOOREA)
Medical condition
Carcinoma, Non-Small-Cell Lung
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
500
Study type
Observational
Age
18 Years - 130 Years
Date
Study Start Date: 16 Jul 2019
Primary Completion Date: 29 Feb 2024
Study Completion Date: 29 Feb 2024
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Mar 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Cohort 1 Cohort 1, including patients without surgical resection, will be defined as unresectable stage III NSCLC | - |
| Cohort 2 Cohort 2,including patients with surgical resection, will be defined as resectable stage III NSCLC | - |
